Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499359 | 0.85 | TSHR (0.47) | KDM4ETSHRUSP2ALOX15ALDH1A1 | |
| SCHEMBL13499249 | 0.83 | TSHR (0.45) | KDM4ETSHRUSP2ALOX15ALDH1A1 | |
| SCHEMBL13499449 | 0.83 | KDM4E (0.45) | KDM4ETSHRUSP2ALOX15ALDH1A1 | |
| SCHEMBL13499343 | 0.82 | LTA4H (0.46) | KDM4E | |
| SCHEMBL13499448 | 0.79 | KDM4E (0.42) | KDM4ETSHRUSP2ALOX15ALDH1A1 | |
| SCHEMBL13499269 | 0.76 | KDM4E (0.56) | KDM4ETSHRUSP2ALOX15ALDH1A1 | |
| SCHEMBL13499254 | 0.75 | KDM4E (0.44) | KDM4ETSHRUSP2ALOX15ALDH1A1 | |
| SCHEMBL13499419 | 0.72 | KDM4E (0.44) | KDM4ETSHRALDH1A1HPGDMEN1 | |
| SCHEMBL13499374 | 0.70 | TSHR (0.45) | KDM4ETSHRUSP2ALOX15ALDH1A1 | |
| SCHEMBL13307246 | 0.68 | KDM4E (0.42) | KDM4ETSHRUSP2ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | KDM4E 3793/4885TSHR 937/4885USP2 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.